About the Journal

Download [This article belongs to Volume - 140, Issue - 01]

Abstract : The antihyperglycemic medication Repaglinide (RG) is used to treat non-insulin-dependent diabetic mellitus., that stimulates insulin release from pancreatic beta cells by binding to and ultimately activating ATP dependent potassium channels. The purpose of this study was to investigate the protective effect of Repaglinide on liver and kidney tissue of diabetic albino rats that had been induced by alloxan. In this investigation, 20 male white adult albino rats were separated into two groups (10 rats) were applied to produce diabetes mellitus (type II) using alloxan monohydrate, and the second group (10 rats) were administered normal saline intraperitonealy. These animals were divided in to four groups: Group 1 Normal control non-diabetic rats were only administrated distilled water; Non-diabetic rats in Group 2 were given 4 mg/kg/day of repaglinide; Group 3 Diabetic control who were given alloxan i.p. and administrated distilled water orally but were not given any medications; Groups 4 Diabetic rats treated with repaglinide 4mg/kg/day. According to the histological sections all of non-diabetic control, non-diabetic rats treated with repaglinide and in diabetic rats treated with repaglinide had normal histology of the liver and kidney, whereas diabetic control had hepatocytes degeneration and lymphocyte infiltration in both liver and kidney. On the other hand, rats treated with repaglinide showed a noticeable recovery of liver and kidney tissues, suggesting that (RG) might be a useful treatment for treating and avoiding harmful alterations in these tissues.

Copyright © 2020 All rights reserved | Bulletin of National Institute of Health Sciences